JPLA
ALDX icon

Joseph P. Lucia & Associates’s Aldeyra Therapeutics ALDX Stock Holding History

Joseph P. Lucia & Associates’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,732
Closed -$138K – 170
2025
Q4 		$138K Sell
26,732
-4,859
-15% -$25K 0.05% 165
2025
Q3 		$165K Sell
31,591
-32
-0.1% -$167 0.06% 159
2025
Q2 		$121K Sell
31,623
-35
-0.1% -$90 0.05% 151
2025
Q1 		$182K Sell
31,658
-12
-0% -$71 0.08% 139
2024
Q4 		$158K Sell
31,670
-62
-0.2% -$318 0.07% 143
2024
Q3 		$171K Buy
31,732
+3,480
+12% +$16.6K 0.08% 132
2024
Q2 		$93.5K Hold
28,252
– – 0.05% 121
2024
Q1 		$92.4K Hold
28,252
– – 0.05% 121
2023
Q4 		$99.2K Sell
28,252
-79
-0.3% -$244 0.06% 115
2023
Q3 		$189K Buy
28,331
+5,550
+24% +$41.2K 0.13% 104
2023
Q2 		$191K Sell
22,781
-3,656
-14% -$36K 0.13% 112
2023
Q1 		$263K Buy
26,437
+14,437
+120% +$102K 0.18% 95
2022
Q4 		$62.3K Buy
+12,000
New +$68.6K 0.05% 113

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Joseph P. Lucia & Associates's ALDX Position: Q1 2026 in Review

Joseph P. Lucia & Associates sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 26,732 shares — an estimated $138K sold.

Joseph P. Lucia & Associates first reported a position in ALDX in Q4 2022 and held it in 13 quarters. The position peaked at $263K in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Joseph P. Lucia & Associates reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 26,732 Aldeyra Therapeutics shares in Q1 2026, an estimated $138K.
  • Joseph P. Lucia & Associates first reported a position in Aldeyra Therapeutics in Q4 2022 and held it in 13 quarters.
  • Joseph P. Lucia & Associates's Aldeyra Therapeutics position peaked at $263K in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Joseph P. Lucia & Associates's 13F filing for Q1 2026, filed 15 May 2026.